Summary
| Excerpt |
|---|
| ACRIN 6668, ...... Main Objective: Participants:Study Design Summary:The primary purpose of this study is to determine if the SUV measurement from FDG-PET imaging shortly after treatment is a useful predictor of long-term clinical outcome (survival) after definitive chemoradiotherapy. Eligible patients are those older than 18 years with AJCC clinical stage IIB/III non-small cell lung carcinoma who are being planned for definitive concurrent chemoradiotherapy (inoperable disease). A total of 250 participants will be enrolled, including at least 75 with stage IIB/IIIA and at least 75 with stage IIIB disease. A baseline whole-body FDG-PET scan will be performed. Follow up after chemoradiotherapy will comprise restaging of the disease and a second whole-body FDG-PET scan 12 to 16 weeks after the completion of radiotherapy (at least 4 weeks after adjuvant chemotherapy). Acknowledgements This shared data set was provided by <<<others>>>> in collaboration with the American College of Radiology Imaging network (ACRIN). Many thanks are due to the ACRIN 6668 trial team, and all the patients participating in the study. This study was supported by ACRIN, which received funding from the National Cancer Institute through <<<>>>, under the American Recovery and Reinvestment ACT of 2009 (ARRA) and UO1 <<<>>>. |
...